Completed PHASE2 INTERVENTIONAL 2-arm NCT00961467

RMPT for Relapsed/Refractory Multiple Myeloma (RMPT)

Lenalidomide, Melphalan, Prednisone, and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma

Sponsor: Fondazione EMN Italy Onlus

Interventions Revlimid, Melphalan, Prednisone, Thalidomide

Updated 6 times since 2017 Last updated: May 9, 2016 Started: Feb 28, 2007 Primary completion: Mar 31, 2008 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Myeloma and is currently completed. Fondazione EMN Italy Onlus leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondazione EMN Italy Onlus

Data source: Fondazione EMN Italy Onlus

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Torino, Italy